Biodesix, Inc. (NASDAQ:BDSX) Short Interest Update

Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) was the recipient of a large growth in short interest in February. As of February 28th, there was short interest totalling 973,200 shares, a growth of 24.6% from the February 13th total of 781,300 shares. Based on an average daily trading volume, of 428,500 shares, the short-interest ratio is currently 2.3 days. Currently, 2.2% of the shares of the stock are sold short.

Biodesix Price Performance

NASDAQ BDSX traded down $0.01 during trading hours on Thursday, hitting $0.80. 90,963 shares of the company's stock traded hands, compared to its average volume of 277,647. The company has a market capitalization of $117.22 million, a PE ratio of -2.04 and a beta of 1.10. The company has a debt-to-equity ratio of 1.30, a current ratio of 3.40 and a quick ratio of 3.40. Biodesix has a 52-week low of $0.64 and a 52-week high of $2.04. The firm's 50-day moving average is $0.96 and its 200-day moving average is $1.34.

Biodesix (NASDAQ:BDSX - Get Free Report) last issued its earnings results on Monday, March 3rd. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.01. Biodesix had a negative return on equity of 275.79% and a negative net margin of 66.84%. The business had revenue of $20.43 million for the quarter, compared to analysts' expectations of $19.92 million. Equities analysts forecast that Biodesix will post -0.35 EPS for the current fiscal year.

Remove Ads

Insider Activity

In related news, CEO Scott Hutton sold 83,660 shares of the company's stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $0.92, for a total transaction of $76,967.20. Following the completion of the transaction, the chief executive officer now owns 701,947 shares in the company, valued at $645,791.24. This represents a 10.65 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 128,702 shares of company stock worth $118,406 in the last quarter. Corporate insiders own 69.20% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Balyasny Asset Management L.P. purchased a new position in Biodesix during the fourth quarter worth about $29,000. Barclays PLC raised its position in shares of Biodesix by 1,140.5% during the 3rd quarter. Barclays PLC now owns 23,036 shares of the company's stock valued at $41,000 after buying an additional 21,179 shares during the period. Boothbay Fund Management LLC purchased a new stake in shares of Biodesix during the 4th quarter valued at approximately $52,000. MYDA Advisors LLC acquired a new position in Biodesix in the fourth quarter valued at approximately $76,000. Finally, Cubist Systematic Strategies LLC grew its position in Biodesix by 385.9% in the fourth quarter. Cubist Systematic Strategies LLC now owns 51,024 shares of the company's stock worth $78,000 after acquiring an additional 40,524 shares during the period. Institutional investors and hedge funds own 20.96% of the company's stock.

Wall Street Analyst Weigh In

Separately, William Blair restated an "outperform" rating on shares of Biodesix in a research report on Tuesday, March 4th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $2.95.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.